results from the breselibet trial of brentuximab vedotin chemotherapy for r/r hodgkin lymphoma
Published 1 month ago • 82 plays • Length 3:24Download video MP4
Download video MP3
Similar videos
-
3:47
brentuximab vedotin plus chemotherapy prior to asct in r/r hodgkin lymphoma
-
3:26
phase 2 trial of brentuximab vedotin plus avd for non-bulky limited-stage hodgkin lymphoma
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
1:14
brentuximab vedotin combined with nivolumab for hodgkin lymphoma
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
1:04
updates on the use of brentuximab vedotin in later-stage hl
-
1:23
ipilimumab, nivolumab & brentuximab vedotin for r/r hodgkin lymphoma
-
5:25
asco 2023 highlights on nivolumab in advanced stage classic hodgkin lymphoma: the swog s1826 study
-
46:33
understanding biomarker testing
-
6:50
nivolumab-avd improved pfs versus brentuximab vedotin-avd in patients with advanced stage hl
-
2:23
real-world data on brentuximab vedotin with chemotherapy in hodgkin lymphoma
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
1:27
treatment options for patients with hodgkin lymphoma who progress after brentuximab vedotin
-
3:31
brentuximab vedotin plus eshap: complete remission in r/r hodgkin lymphoma
-
2:39
an update on the cobra trial: pet-response adapted treatment with brentuximab vedotin for hl
-
3:23
brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical hodgkin lymphoma
-
2:16
determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
-
1:11
brentuximab vedotin: current status and future considerations for this agent in hl treatment
-
1:59
updates on the use of nivolumab in hodgkin lymphoma & how this agent may impact treatment
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
2:55
everolimus and itacitinib in patients with hl r/r to brentuximab vedotin and checkpoint inhibitors